PETV PetVivo Holdings Inc

$PETV Materials and Methods Eighteen rhesus macaques with radiographically conrmed multi-joint OA were selected. Prior to and after injections, mobility was assessed using walking speed, accelerometry, blinded subjective clinical scoring, reach testing, and goniometry. Data was assessed using equivalence testing, as well as mixed-effects model statistics. Preliminary analyses demonstrated signicant improvements in walking speed following treatment. Walking speed increased in 91.6% of treated animals, with a mean improvement of 0.22 ± 0.11 m/s (median 0.21 m/s; range 0.03–0.41 m/s). Mixed-effects modeling demonstrated a signicant effect of timepoint on walking speed (F₃,₃₃ = 18.24, p < 0.000001). Compared with baseline, walking speed was signicantly increased at week 1 (p = 0.0002), week 2 (p < 0.0001), and week 3 (p < 0.0001).

$PETV they've just replaced the board and now we're waiting on some sales updates. Could be a good time to add more.

$PETV PetVivo's primate study evaluating Spryng® with OsteoCushion® Technology in rhesus macaques demonstrated a statistically significant mean walking speed improvement of 0.22 ± 0.11 meters per second within three weeks of treatment. This rapid, non-invasive mobility gain stands in stark contrast to the human knee replacement market, where standard total knee arthroplasty requires extensive structural trauma and lengthy rehabilitation—yet only 50% of patients achieve optimal mobility scores in complex tasks like descending stairs after six months. Because non-human primates share virtually identical joint biomechanics and disease progression with humans, PetVivo's ability to achieve these physical improvements while seamlessly integrating into synovial tissues with minimal local inflammation strongly validates its human market potential. This data positions the injectable hydrogel as a highly viable, pre-surgical therapeutic alternative.

Yesterdays Recap: $PETV ANNOUNCES RELEASE OF TWO RESEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES $AMLM Announces Appointment of Independent Directors and Launch of Shareholder Ambassador Program

$PETV 2 abstracts about using spryng on monkeys, while vets don’t want it. I’m waiting on abstracts about hamsters personally!

$PETV Very Impressive ! Specifically, Mr. Handley was one of the founders and on the management team of Vessix Vascular, Inc. in Laguna Hills California from 2011 to 2012. As a result of his work at Vessix Vascular the company was acquired for $435M by Boston Scientific. Before his time at Vessix Vascular, Mr. Handley was Global Head of Regulatory at Acclarent (that was acquired by Johnson & Johnson) from 2010 – 2011 and assisted in the integration of the $785M acquisition of Acclarent and their five product lines and driving the global revenue growth of the Ethicon franchise for ENT products. Prior to working with Acclarent/J&J, Mr. Handley was the Global Vice President of Regulatory Affairs and Chief Compliance Officer at Spectranetics Corporation, a NASDAQ listed (SPNC)

$PETV Michael Handley Joins PetVivo Holdings, Inc. Board of Directors MINNEAPOLIS, MN, US, Sept. 22, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, today announced the appointment of Michael K. Handley to its Board of Directors, effective September 22, 2026.